Rare Cancer Drug Developer Embraced by French Pharmaceutical Company Completes 3 Trillion Won Deal

Regarding French pharmaceutical company Servier’s acquisition process, AI Day1 LLC—a principal financial investor in Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)—sold all of its common shares on April 9 at $21.50 per share in cash under Servier’s subsidiary tender offer.

On April 23, Adam Dubow, General Counsel and Corporate Secretary, and board member Natalie C. Holles had all their equity-based compensation—common stock, stock options, and RSUs—accelerated and settled in cash on the same terms, fully divesting their stakes.

Also on April 23, Servier announced it had completed the acquisition of Day One at $21.50 per share, valuing the company at approximately $2.5 billion (about KRW 3.4 trillion). As a result, Day One’s common stock was delisted from NASDAQ, and the business became a wholly owned subsidiary of Servier.

Day One is a U.S. biotech firm with a targeted oncology pipeline for rare cancers, including OJEMDA (tovorafenib) for pediatric low-grade glioma. Through this transaction, Servier strengthens its oncology portfolio and U.S. market presence in pediatric brain tumors and other rare tumor indications.